Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RH genotype-matched D-positive red blood cells are a specialized blood product intervention developed by the Children's Hospital of Philadelphia for the treatment of chronically transfused patients with sickle cell disease. This approach targets patients who are genetically D-positive but have developed anti-D antibodies, a condition that usually necessitates lifelong transfusion with D-negative blood. By using precise RHD genotyping to match donor units (specifically from Black donors to ensure better overall antigen matching) with recipients, the protocol aims to safely provide D-positive blood without restimulating anti-D antibodies. This strategy is intended to improve the management of Rh alloimmunization, optimize the use of valuable donor units, and alleviate the strain on Rh-negative blood inventories.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RH genotype-matched D-positive red blood cells.